Literature DB >> 17692514

Activation of estrogen receptor-beta by a special extract of Rheum rhaponticum (ERr 731), its aglycones and structurally related compounds.

Jannette Wober1, Frank Möller, Tobias Richter, Catharina Unger, Carmen Weigt, Anett Jandausch, Oliver Zierau, Reinhard Rettenberger, Marietta Kaszkin-Bettag, Günter Vollmer.   

Abstract

The special extract ERr 731 from the roots of Rheum rhaponticum is the major constituent of Phytoestrol N which is used for the treatment of climacteric symptoms in menopausal women. However, the molecular mode of action of ERr 731 was unknown. For the first time, ERr 731 and its aglycones trans-rhapontigenin and desoxyrhapontigenin were investigated with regard to the activation of the estrogen receptor-alpha or estrogen receptor-beta (ERalpha, ERbeta). The related hydroxystilbenes cis-rhapontigenin, resveratrol and piceatannol were studied as comparators. As controls, 17beta-estradiol or the selective ERalpha-(propylpyrazoltriol) or ERbeta-agonists (diarylpropionitril) were used. Neither in ERalpha-expressing yeast cells, in the ERalpha-responsive Ishikawa cells, nor in human endometrial HEC-1B cells transiently transfected with the ERalpha an activation of ERalpha by ERr 731 or the other single compounds was detected. Furthermore, an antiestrogenic effect was not observed. In contrast in human endometrial HEC-1B cells transiently transfected with the ERbeta, 100 ng/ml ERr 731 and the single compounds significantly induced the ERbeta-coupled luciferase activity in a range comparable to 10(-8)M 17beta-estradiol. All effects were abolished with the pure ER antagonist ICI 182780, indicating an ER-specific effect. The ERbeta agonistic activity by ERr 731 could be of importance for its clinical use, as central functions relevant to climacteric complaints are proposed to be mediated via ERbeta activation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17692514     DOI: 10.1016/j.jsbmb.2007.04.002

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  7 in total

1.  Treatment of menopausal symptoms by an extract from the roots of rhapontic rhubarb: the role of estrogen receptors.

Authors:  Günter Vollmer; Anja Papke; Oliver Zierau
Journal:  Chin Med       Date:  2010-02-19       Impact factor: 5.455

Review 2.  Botanicals and Their Bioactive Phytochemicals for Women's Health.

Authors:  Birgit M Dietz; Atieh Hajirahimkhan; Tareisha L Dunlap; Judy L Bolton
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

Review 3.  Botanical modulation of menopausal symptoms: mechanisms of action?

Authors:  Atieh Hajirahimkhan; Birgit M Dietz; Judy L Bolton
Journal:  Planta Med       Date:  2013-02-13       Impact factor: 3.352

4.  Rheum rhaponticum Extract (ERr 731): Postmarketing Data on Safety Surveillance and Consumer Complaints.

Authors:  Jyh-Lurn Chang; Michael B Montalto; Peter W Heger; Eva Thiemann; Reinhard Rettenberger; Jürgen Wacker
Journal:  Integr Med (Encinitas)       Date:  2016-06

5.  The short-term effects of estradiol, raloxifene, and a phytoestrogen in women with perimenopausal depression.

Authors:  Peter J Schmidt; Shau-Ming Wei; Pedro E Martinez; Rivka R Ben Dor; Gioia M Guerrieri; Paula P Palladino; Veronica L Harsh; Howard J Li; Paul Wakim; Lynnette K Nieman; David R Rubinow
Journal:  Menopause       Date:  2021-01-15       Impact factor: 3.310

6.  Rhaponticin suppresses osteosarcoma through the inhibition of PI3K-Akt-mTOR pathway.

Authors:  Suresh Mickymaray; Faiz Abdulaziz Alfaiz; Anand Paramasivam; Vishnu Priya Veeraraghavan; Nanthini Devi Periadurai; Krishna Mohan Surapaneni; Guangfeng Niu
Journal:  Saudi J Biol Sci       Date:  2021-05-08       Impact factor: 4.219

7.  Photoprotective and antioxidant effects of Rhubarb: inhibitory action on tyrosinase and tyrosine kinase activities and TNF-α, IL-1α and α-MSH production in human melanocytes.

Authors:  Jéssica P S Silveira; Leonardo N Seito; Samara Eberlin; Gustavo C Dieamant; Cecília Nogueira; Maria C V Pereda; Luiz C Di Stasi
Journal:  BMC Complement Altern Med       Date:  2013-02-27       Impact factor: 3.659

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.